Thermo Fisher Scientific, Danaher, Sonnet BioTherapeutics, AbbVie, Moderna, Vertex Pharmaceuticals, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that focus on developing and commercializing products and technologies based on biological processes—most commonly new drugs, diagnostic tools, or genetic therapies. Investors in these stocks typically bet on breakthroughs in areas like genomics, immunotherapy, and personalized medicine, often accepting higher volatility and longer timelines in exchange for the potential of substantial returns if a company’s research succeeds. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE:TMO traded down $8.37 on Monday, reaching $426.49. 1,151,444 shares of the company's stock were exchanged, compared to its average volume of 2,399,334. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $161.00 billion, a price-to-earnings ratio of 25.04, a price-to-earnings-growth ratio of 2.31 and a beta of 0.77. The business has a fifty day moving average of $409.39 and a 200-day moving average of $475.87. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88.
Read Our Latest Research Report on TMO
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
NYSE:DHR traded down $6.03 on Monday, reaching $198.82. 1,934,196 shares of the company's stock were exchanged, compared to its average volume of 4,187,505. The business has a fifty day moving average of $196.05 and a 200-day moving average of $206.13. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher has a 52-week low of $171.00 and a 52-week high of $281.70. The firm has a market capitalization of $142.29 billion, a price-to-earnings ratio of 38.68, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77.
Read Our Latest Research Report on DHR
Sonnet BioTherapeutics (SONN)
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Sonnet BioTherapeutics stock traded up $4.90 during trading on Monday, reaching $10.07. The stock had a trading volume of 35,761,024 shares, compared to its average volume of 1,222,614. Sonnet BioTherapeutics has a 52-week low of $1.08 and a 52-week high of $25.86. The business has a 50 day moving average price of $1.75 and a 200 day moving average price of $1.57.
Read Our Latest Research Report on SONN
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE:ABBV traded down $1.97 during trading hours on Monday, reaching $190.48. The stock had a trading volume of 1,376,355 shares, compared to its average volume of 6,995,225. AbbVie has a 1 year low of $163.81 and a 1 year high of $218.66. The firm's 50 day moving average is $187.01 and its 200-day moving average is $189.11. The stock has a market capitalization of $336.46 billion, a price-to-earnings ratio of 81.05, a P/E/G ratio of 1.28 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76.
Read Our Latest Research Report on ABBV
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
NASDAQ MRNA traded down $0.65 during trading on Monday, reaching $32.99. 3,530,020 shares of the company's stock were exchanged, compared to its average volume of 11,209,707. The company has a 50 day moving average price of $27.21 and a two-hundred day moving average price of $31.09. The stock has a market cap of $12.76 billion, a P/E ratio of -3.78 and a beta of 1.84. Moderna has a 1 year low of $23.15 and a 1 year high of $127.20.
Read Our Latest Research Report on MRNA
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
VRTX stock traded up $3.31 during trading on Monday, hitting $472.16. 221,918 shares of the company's stock were exchanged, compared to its average volume of 1,554,477. The business has a 50-day moving average price of $447.71 and a two-hundred day moving average price of $461.11. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $121.25 billion, a price-to-earnings ratio of -120.45 and a beta of 0.41. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88.
Read Our Latest Research Report on VRTX
argenex (ARGX)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
ARGX stock traded up $3.91 during midday trading on Monday, reaching $564.15. 150,969 shares of the company were exchanged, compared to its average volume of 364,009. The company has a market cap of $34.53 billion, a price-to-earnings ratio of 34.89, a price-to-earnings-growth ratio of 1.03 and a beta of 0.37. argenex has a 1-year low of $457.42 and a 1-year high of $678.21. The stock's 50-day simple moving average is $567.54 and its 200 day simple moving average is $601.62.
Read Our Latest Research Report on ARGX
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
